Artivion reports first quarter 2025 financial results

First quarter highlights: achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a gaap basis and 4% on a non-gaap constant currency basis net loss was $(0.5) million, or $(0.01) per fully diluted share and non-gaap net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025 adjusted ebitda increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 2024 30-day data from endospan's nexus triomphe ide trial presented at the aats annual meeting demonstrated a 63% reduction in the major adverse event (mae) rate compared with reference performance goal submitted the clinical module of the pre-market approval application (pma) to the fda for the amds hybrid prosthesis atlanta , may 5, 2025 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended march 31, 2025. "i am pleased with our first quarter results as we returned to normal operations following our previously disclosed cybersecurity incident while making substantial progress on our strategic growth initiatives.
AORT Ratings Summary
AORT Quant Ranking